Carbamazepine-induced antinuclear antibodies and systemic lupus erythematosus-like syndrome.
A 20-year-old woman developed a systemic lupus erythematosus (SLE)-like syndrome and a positive antinuclear antibody (ANA) soon after initiation of carbamazepine (CBZ) therapy. Symptoms and serology became normal after CBZ was discontinued. CBZ-induced SLE is an important but underecognized phenomenon.
De Giorgio
C M
CM
Department of Neurology, University of Southern California School of Medicine, Los Angeles 90033.
Rabinowicz
A L
AL
Olivas
R D
RD
D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis*; D002220:Carbamazepine / Q000009:adverse effects* / Q000627:therapeutic use; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000276:immunology
D000974:Antibodies, Antinuclear; D002220:Carbamazepine